Answers are grounded in this paper and cite their sources.
Consensus guideline updates diagnostic criteria and genetic profiles for lymphoid neoplasms, highlighting refined management for early-stage disease and targeted therapy.
A revision of the nearly 8-year-old World Health Organization classification of the lymphoid neoplasms and the accompanying monograph is being published. It reflects a consensus among hematopathologists, geneticists, and clinicians regarding both updates to current entities as well as the addition of a limited number of new provisional entities. The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies. The major changes are reviewed with an emphasis on the most important advances in our understanding that impact our diagnostic approach, clinical expectations, and therapeutic strategies for the lymphoid neoplasms.
No takes yet. Share an insight, caveat, or question.
Swerdlow et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: